Allergan Specialty Therapeutics, Inc.
Allergan Specialty Therapeutics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1983, the company has established itself as a leader in developing innovative treatments across various therapeutic areas, including ophthalmology, medical aesthetics, and neuroscience. Allergan is renowned for its core products, such as Botox® and Juvederm®, which have revolutionised aesthetic medicine and pain management. The company’s commitment to research and development has led to significant milestones, including numerous FDA approvals that underscore its market position. With a strong presence in North America and expanding operations globally, Allergan Specialty Therapeutics continues to set benchmarks in patient care and therapeutic advancements, solidifying its reputation as a trusted name in specialty pharmaceuticals.
DitchCarbon Score
How does Allergan Specialty Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allergan Specialty Therapeutics, Inc.'s score of 35 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Allergan Specialty Therapeutics, Inc.'s reported carbon emissions
Allergan Specialty Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their carbon emissions in kg CO2e, nor any documented initiatives aimed at reducing their carbon footprint. This absence of data suggests that the company may still be in the early stages of formalising its climate commitments or reporting practices. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and setting ambitious targets to reduce greenhouse gas emissions. However, without specific information from Allergan Specialty Therapeutics, it is unclear what their current stance or future plans may be regarding climate action and emissions reduction.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Allergan Specialty Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
